Short Cationic Peptides for Membrane Destabilization

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Current antibacterial peptides are often long and difficult to synthesize, requiring complex processing and culture methods, which limits their economic manufacture and delivery options, and there is a growing need for shorter peptides that can effectively combat antibiotic-resistant bacterial strains.

Innovation Solution

Development of short cationic peptides with specific amino acid combinations, such as AA 1 -AA 2 -AA 1 -X-Y-Z, that exhibit antimicrobial activity through membrane destabilization, offering stability and low toxicity, and can be synthesized using conventional methods for broader application.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If long peptides (20 or more amino acids) are used to span bacterial cell membranes and form pores, then antimicrobial activity is achieved, but synthesis difficulty increases and manufacturing complexity worsens

Engineering Contradiction:
Improveantimicrobial activityVSAvoidsynthesis difficulty
Core Design Contradiction:
ReliabilityVSEase of manufacture

Solution Approach 1:

The patent changes the critical parameter of peptide length from 20+ amino acids to just 3-5 amino acids, fundamentally altering the mechanism from pore formation to membrane destabilization. This parameter change enables both maintained antimicrobial activity and dramatically simplified synthesis

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention extracts only the essential functional elements needed for antimicrobial activity (cationic charge and hydrophobic interaction capability) while removing the excessive length required for pore formation. The core antimicrobial function is preserved in a minimized peptide structure

Inventive Principle:
Principle #2Taking out (Extraction)

2Reliability

If long peptides are used to ensure sufficient membrane-spanning length, then pore formation capability is achieved, but processing steps and cultural requirements increase

Engineering Contradiction:
Improvemembrane pore formationVSAvoidprocessing complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the mechanism parameter from pore formation to membrane destabilization, allowing short peptides to achieve antimicrobial effect without complex processing. The peptides directly interact with and destabilize bacterial membranes through electrostatic and hydrophobic interactions

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention uses simple, short-lived peptide structures that can be easily synthesized and discarded after use, replacing complex, stable pore-forming peptides. The short peptides achieve their function rapidly and do not require complex processing or purification

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

3Reliability

If conventional long peptides are used for antimicrobial therapy, then bacterial killing activity is achieved, but delivery options are limited requiring injection

Engineering Contradiction:
Improvebacterial killing activityVSAvoiddelivery options
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the peptide length parameter to enable alternative delivery routes. The short length allows absorption across nasal mucosa and other non-injectable routes, expanding administration options while maintaining bacterial killing activity through direct membrane interaction

Inventive Principle:
Principle #35Parameter changes

4Reliability

If long peptides are synthesized to span cell membranes, then antimicrobial efficacy is achieved, but economic manufacture becomes difficult

Engineering Contradiction:
Improveantimicrobial efficacyVSAvoidmanufacture economy
Core Design Contradiction:
ReliabilityVSProductivity

Solution Approach 1:

The patent changes the economic parameter by reducing peptide length to 3-5 amino acids, enabling cost-effective synthesis through standard chemical methods. The short peptides can be manufactured economically while maintaining antimicrobial efficacy through their cationic and hydrophobic properties

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The invention employs inexpensive, short peptide sequences that can be synthesized cheaply using standard chemical peptide synthesis methods, replacing expensive, complex long peptides. The simplicity of the sequences enables economical large-scale production

Inventive Principle:
Principle #27Cheap short-living objects (Disposable)

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

These peptides demonstrate broad-spectrum antimicrobial activity, rapid bacterial killing, and resistance to enzymatic degradation, making them suitable for various therapeutic and agricultural uses, including topical administration and treatment of infections like onychomycosis.

Implementation Method 1

these peptides have a net positive charge and a propensity to form amphiphilic α-helix or β-sheet structures upon interaction with the outer phospholipid bilayer in bacterial cell membranes

Methodology Applied
Scientific EffectElectrostatic interaction: Coulomb's Law

Implementation Method 2

AA 2 is an amino acid with a large lipophilic R group selected from tributyl tryptophan (Tbt) or a biphenylalanine derivative

Methodology Applied
Scientific EffectHydrophobic interaction: Hydrophobe

Data Source

PatentEP2235041B1Antimicrobial compounds
Publication Date: 2014.03.05 LYTIX BIOPHARMA AS
  • EP2235041B1 patent drawingFigure 1
  • EP2235041B1 patent drawingFigure 2
  • EP2235041B1 patent drawingFigure 3

AI summary

The present invention relates to a compound of formula (I) AA-AA-AA-X-Y-Z wherein, in any order, 2 of said AA (amino acid) moieties are cationic amino acids and 1 of said AA is an amino acid with a lipophilic R group, the R group having 14-27 non-hydrogen atoms; X is a N atom, which may be substituted by a branched or unbranched C1-C10 alkyl or aryl group which group may incorporate up to 2 heteroatoms selected from N, O and S; Y represents a group selected from -Ra-Rb-, -Ra-Rb-Rb- and -Rb-Rb-Ra- wherein Ra is C, O, S or N, and Rb is C; each of Ra and Rb may be substituted by C1-C4 alkyl groups or unsubstituted; and Z is a group comprising 1 to 3 cyclic groups each of 5 or 6 non-hydrogen atoms, 2 or more of the cyclic groups may be fused and one or more of the cyclic groups may be substituted; the Z moiety incorporates a maximum of 15 non-hydrogen atoms; and wherein the bond between Y and Z is a covalent bond between Ra or Rb of Y and a non-hydrogen atom of one of the cyclic groups of Z. The invention further relates to formulations containing these compounds and their uses in therapy, particularly as antimicrobial or antitumoural agents.